Remission of an iatrogenic kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mtor inhibitor everolimus;Remission eines iatrogenen kaposi-sarkoms bei myasthenia gravis nach umstellung der immunsuppression auf den mtor-inhibitor everolimus

Hautarzt

Volumn 63, Issue 7, 2012, Pages 573-576

  Krengel, S ^a   Satzger, I ^a   Alter, M ^a   Kapp, A ^a   Gutzmer, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Everolimus; Immunosuppression; Kaposi sarcoma; MTOR inhibitor; Myasthenia gravis

Indexed keywords

AZATHIOPRINE; EVEROLIMUS; NICOTINIC RECEPTOR; PREDNISONE;

AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; MALE; MYASTHENIA GRAVIS; ORGAN TRANSPLANTATION;

AGED, 80 AND OVER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYASTHENIA GRAVIS; REMISSION INDUCTION; SARCOMA, KAPOSI; SIROLIMUS; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84864375535     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-011-2274-y     Document Type: Article

References (26)

1. Atasoyu EM, Bilgi O, Kinalp C et al (2009) Cutaneous Kaposi's sarcoma following immunosuppressive therapy for membranoproliferative glomerulonephritis. Clin Nephrol 72:420-421
2. Babel N, Eibl N, Ulrich C et al (2008) Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 10:59-62 (Pubitemid 351171313)
3. Bedrick JJ, Savino PJ, Schatz NJ (1981) Conjunctival Kaposi's sarcoma in a patient with myasthenia gravis. Arch Ophthalmol 99:1607-1609 (Pubitemid 11014333)
4. Boratynska M, Zmonarski SC, Klinger M (2006) Reccurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 6:2018-2022 (Pubitemid 44855709)
5. Bugelski PJ, Volk A, Walker MR et al (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol 29:435-466
6. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV (2004) Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77:760-762 (Pubitemid 38366986)
7. Campistol JM, Schena FP (2007) Kaposi's sarcoma in renal transplant recipients - the impact of proliferation signal inhibitors. Nephrol Dial Transplant 22(Suppl 1):i17-i22 (Pubitemid 47073740)
8. Chiurchiu C, Carreno CA, Schiavelli R et al (2010) Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 42:277-279
9. Guba M, Breitenbuch P von, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128-135 (Pubitemid 34155123)
10. Guenova E, Metzler G, Hoetzenecker W et al (2008) Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 144:692-693 (Pubitemid 351724445)
11. Gutierrez-Dalmau A, Sanchez-Fructuoso A, Sanz-Guajardo A et al (2005) Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 37:3836-3838 (Pubitemid 43015184)
12. Hoff M, Rodevand E (2005) Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomatosis. Rheumatol Int 25:238-240 (Pubitemid 40576794)
13. Kauffman HM, Cherikh WS, Cheng Y et al (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883-889 (Pubitemid 41552882)
14. Lebbe C, Euvrard S, Barrou B et al (2006) Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 6:2164-2168 (Pubitemid 44199551)
15. Louthrenoo W, Kasitanon N, Mahanuphab P et al (2003) Kaposi's sarcoma in rheumatic diseases. Semin Arthritis Rheum 32:326-333 (Pubitemid 36459282)
16. Mezalek ZT, Harmouche H, Attar NE et al (2007) Kaposi's sarcoma in association with Behcet's disease: case report and literature review. Semin Arthritis Rheum 36:328-331 (Pubitemid 46533853)
17. Monaco AP (2009) The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 87:157-163
18. Nassar D, Schartz NE, Bouche C et al (2010) Kaposi's sarcoma after long-acting steroids: time until remission and drug washout. Dermatology 220:159-163
19. Saggar S, Zeichner JA, Brown TT et al (2008) Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. Arch Dermatol 144:654-657 (Pubitemid 351724427)
20. Sanchez-Fructuoso A, Conesa J, Perez F et al (2006) Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 38:2451-2452 (Pubitemid 44693718)
21. Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233-242
22. Snyder RA, Schwartz RA (1982) Telangiectatic Kaposi's sarcoma. Occurrence in a patient with thymoma and myasthenia gravis receiving long-term immunosuppressive therapy. Arch Dermatol 118:1020-1021 (Pubitemid 13240986)
23. Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317-1323 (Pubitemid 40411498)
24. Svrcek M, Tiret E, Bennis M et al (2009) KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. Dis Colon Rectum 52:154-158
25. Valantine H (2007) Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 26:557-564 (Pubitemid 46818047)
26. Vogt T, Brockmeyer N, Kutzner H, Schofer H (2008) Short German guidelines: angiosarcoma and Kaposi sarcoma. J Dtsch Dermatol Ges 6(Suppl 1):19-24